Latest From medac GmbH
Seven new drug applications got the thumbs up this week from the EMA's drug evaluation committee, the CHMP. Their EU approval should now be a formality. Two new Shionogi treatments are set for approval, as are two orphan products – one from Medac, the other from AOP Orphan Pharmaceuticals. Pfizer got the OK for one biosimilar but has withdrawn an application for another.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
- In Vitro Diagnostics
- Therapeutic Areas
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- medac GmbH
- medac GMBH
- Medac GMBH
- Senior Management
W. Mohr, Pres.
Heiner Will, Chief Marketing Officer
- Contact Info
Phone: (49) 4103 8006 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.